Literature DB >> 17532546

Lack of protection of mice against Staphylococcus aureus despite a significant immune response to immunization with a DNA vaccine encoding collagen-binding protein.

Roseline Therrien1, Pierre Lacasse, Gilles Grondin, Brian G Talbot.   

Abstract

Collagen-binding protein (CNA) is the major Staphylococcus aureus adhesin responsible for high affinity binding to collagen and is assumed to be a major virulence factor in infection and disease. Mutants lacking the cna gene are less virulent than the parent strain in models of septic arthritis, osteomyelitis, keratinitis, and endocarditis. In order to investigate the immunological and protective properties of a CNA-based DNA vaccine, a eukaryotic expression vector pCNA was constructed which expressed the collagen-binding domain of this adhesin in transfected cells. Three groups of 11 Balb/c mice received three injection of either pCNA, the empty expression vector (pCI) or PBS. Those injected with pCNA showed hi titre (64000) antibody and evidence of a cell-mediated immune response (CMI). The anti-CNA antibodies recognized the intact bacteria and prevented binding to collagen in vitro. However, the vaccination did not protect against bacterial challenge using the intra-peritoneal route of infection. Moreover, S. aureus that had been treated with sera from vaccinated mice caused a more severe infection than bacteria treated with sera from non-vaccinated mice. In summary, DNA vaccination against CNA produced a strong antibody and cellular response in mice but failed to protect from i.p. infection by S. aureus.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17532546     DOI: 10.1016/j.vaccine.2007.04.067

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans.

Authors:  Clayton Harro; Robert Betts; Walter Orenstein; Eun-Jeong Kwak; Howard E Greenberg; Matthew T Onorato; Jon Hartzel; Joy Lipka; Mark J DiNubile; Nicholas Kartsonis
Journal:  Clin Vaccine Immunol       Date:  2010-10-13

Review 2.  A review on anti-adhesion therapies of bacterial diseases.

Authors:  Arezoo Asadi; Shabnam Razavi; Malihe Talebi; Mehrdad Gholami
Journal:  Infection       Date:  2018-10-01       Impact factor: 3.553

3.  Artificial opsonin enhances bacterial phagocytosis, oxidative burst and chemokine production by human neutrophils.

Authors:  Kristy N Katzenmeyer; Luisa M Szott; James D Bryers
Journal:  Pathog Dis       Date:  2017-08-31       Impact factor: 3.166

Review 4.  Targeting the bacteria-host interface: strategies in anti-adhesion therapy.

Authors:  Anne Marie Krachler; Kim Orth
Journal:  Virulence       Date:  2013-05-15       Impact factor: 5.882

Review 5.  Staphylococcus aureus Colonization: Modulation of Host Immune Response and Impact on Human Vaccine Design.

Authors:  Aisling F Brown; John M Leech; Thomas R Rogers; Rachel M McLoughlin
Journal:  Front Immunol       Date:  2014-01-08       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.